Earnings

ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est

Aug 7, 2026 · 06:53 AM ET· updated 1h ago

ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140

Why It Matters

ANI Pharmaceuticals kept its money-making and sales targets the same as before, saying it still expects to earn between $9.19 and $9.69 per share next year. When a company sticks with its plan instead of changing it, that usually means they feel confident things are on track, even if some people expected slightly different numbers.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ANIP76.25

-6.38 (-7.72%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.